Ball Kristine M reported option exercise involving 18,000 derivative units of Oruka Therapeutics, Inc. at $0.00 for $0 on Nov 12, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed Nov 13, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
18,000Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
53,426Direct
Trade date
Nov 12, 2026Option exercise
Filed
Nov 13, 2026, 7:59 PM ET2-day reporting delay
Accession
0000907654-26-000115Code M · Transaction 401427
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 12, 2026Sell1,196$102.10−$122,107.65Trade 401421
Nov 12, 2026Sell1,300$103.09−$134,021.16Trade 401422
Nov 12, 2026Sell2,039$104.16−$212,386.73Trade 401423
Nov 12, 2026Sell10,765$105.31−$1,133,706.29Trade 401424
Nov 12, 2026Sell2,500$106.05−$265,130Trade 401425
Nov 12, 2026Sell200$106.99−$21,397Trade 401426
Nov 12, 2026Option exercise18,000$6.84$123,120Trade 401420
8 transaction rows in this filing. Joint filers share the same rows.

ORKA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ORKA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 21, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −26%1w ago −8.9%1d ago +1.7%
Returns since7d30d90d180d1y

Footnotes in full

F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.62 to $102.61, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.66 to $103.65, inclusive. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.69 to $104.65, inclusive. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.76 to $105.75, inclusive. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.76 to $106.46, inclusive. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.97 to $107.00, inclusive. F8: The option vests as to 1/4 of the underlying shares on May 7, 2025 and as to 1/48 of the underlying shares monthly from May 7, 2025.